Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
11. November 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
07. November 2024 07:00 ET
|
Chimerix, Inc.
– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review...
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
01. November 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18. Oktober 2024 16:31 ET
|
Chimerix, Inc.
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
03. September 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30. August 2024 16:05 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
13. August 2024 07:00 ET
|
Chimerix, Inc.
– Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose...
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
06. August 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05. Juli 2024 16:05 ET
|
Chimerix, Inc.
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to...
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
30. Mai 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...